ROMIDEPSIN
| Brand name | ROMIDEPSIN |
|---|---|
| Active ingredient | ROMIDEPSIN |
| Strength | 27.5MG/5.5ML (5MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | June 2026 |
| Marketing status | RX |
| Code | Expires |
|---|---|
| CGT | December 2026 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.